Rubius Therapeutics (RUBY) Appoints Dannielle Appelhans as Chief Operating Officer
- Dow, S&P 500 end with gains up after bumpy week, but Nike drags
- Over $100 Billion Wiped Off: Bitcoin (BTC) Price Falls As China's Central Bank Vows to Ban Cryptocurrency Trading
- Nike (NKE) Stock Falls On a Revenue Miss and Slashed FY Sales Outlook, Analysts Bullish Despite NT Supply Chain Challenges
- Oil hits highest in almost 3 years as supply tightens
- Here's Why Meredith (MDP) Stock Price Soared 18% in After Hours
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Dannielle Appelhans as chief operating officer, effective August 9, 2021. She will oversee corporate strategy and technical operations.
“Dannielle brings significant experience driving corporate strategy for biopharmaceutical organizations as they evolve from early- to late-stage development, with a particular focus on clinical and commercial manufacturing and scaling supply chains,” said Pablo J. Cagnoni, M.D., president and chief executive officer at Rubius Therapeutics. “As Rubius looks to the future, Dannielle’s contributions will be critical as we expand our reach to serve more patients globally.”
Most recently, Ms. Appelhans served as senior vice president of technical operations and chief technical officer at Novartis Gene Therapies, where she oversaw late-stage development, clinical and commercial manufacturing, supply chain and all supporting operational functions for the gene therapy unit and AAV portfolio. Since 2014, she held positions of increasing responsibility in global supply chain, strategy and operational excellence across several divisions within Novartis. Before joining Novartis, Ms. Appelhans was a senior engagement manager at McKinsey & Company, working in the pharmaceutical operations practice. Earlier in her career she held roles of increasing responsibility at Eli Lilly and Company.
“With its first cancer medicines in the clinic, Rubius has an exciting opportunity to lay the foundation for significant growth as the company scales the organization to reach more patients,” said Dannielle Appelhans, incoming chief operating officer at Rubius Therapeutics. “I look forward to joining a remarkable team and applying my experience and passion for growing global organizations to deliver on the promise of Rubius’ unique pipeline of Red Cell Therapeutics™.”
Ms. Appelhans has an MBA from MIT Sloan School of Management, a Master of Science from Massachusetts Institute of Technology and a Bachelor of Science from the University of Michigan in mechanical engineering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AYRO, Inc (AYRO) Appoints Thomas M. Wittenschlaeger as CEO
- Roblox (RBLX) Launches Listening Parties -- A New Way to Release Music
- Novavax's (NVAX) NanoFlu Influenza Vaccine Phase 3 Results Published in The Lancet ID; Vaccine Produced Significant Enhanced Humoral and Cellular Responses
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!